|

Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981

RECRUITINGPhase 2Sponsored by Chong Kun Dang Pharmaceutical
Actively Recruiting
PhasePhase 2
SponsorChong Kun Dang Pharmaceutical
Started2025-05-12
Est. completion2025-10
Eligibility
Age40 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06954766

Summary

The purpose of this study is to prove that the temporary symptom improvement effect on knee osteoarthritis using CKD-981

Eligibility

Age: 40 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients between 40 years and 80 years old
* Patients who have experiencing knee pain more than 8 weeks
* VAS more than 40 mm
* Kellgren and Lawrence grade 2 and 3 in X' ray knee joint

Exclusion Criteria:

* Previous knee surgery in affected side
* Patients with Rheumatoid arthritis, connective tissue disease, Paget's disease
* Infection of knee joint
* BMI more than 35kg/m2

Conditions2

ArthritisKnee Osteoarthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.